Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

STEP UP co-primary endpoints at 72 weeks*1: semaglutide 7.2 mg semaglutide 2.4 mg Placebo Weight loss 20.7% 17.5% 2.4%5% or more weight loss 93.2% 92.5% 35.7%When evaluating the effect of ...

STEP UP trial showed 21% average weight loss with 7.2 mg Wegovy; one-third lost at least 25% of body weight. Semaglutide 7.2 mg safety was in line with the 2.4 mg dose, though slight risk increase ...

Year to date, Novo Nordisk shares have lost 19% compared with the industry ’s 1.2% decline. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in ...

Novo Nordisk cut ties with Hims & Hers over semaglutide concerns Company alleges illegal sales of unapproved Wegovy alternatives FDA limits compounding of GLP-1 drugs to patient-specific cases ...

Novo Nordisk had a one-year grace period to pay, but never did, and so its patent lapsed in Canada. It lapsed in 2020 when the fee was not received, but it doesn't expire until January.

A box of Ozempic, a semaglutide injection drug used for treating type 2 diabetes and made by Novo Nordisk, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023.

July 9 (UPI) -- The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded ...

Hims, a telehealth platform, joins a growing list of drugmakers that are looking to cash in on Novo Nordisk's lapsed patent on its GLP-1s. It's the first time the company will be operating in ...